- Home
- HTT vs AVIR Comparison
HTT vs AVIR Comparison
Compare HTT & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HTT
High Templar Tech Limited American depositary shares each representing one Class A ordinary share
Current Price
Company Overview
Basic Information| Metric | HTT | AVIR |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | China | United States |
| Employees | 262 | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 412.8M | 434.5M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | HTT | AVIR |
|---|---|---|
| Price | $2.19 | $4.23 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 59.7K | ★ 284.9K |
| Earning Date | 05-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.88 | $2.78 |
| 52 Week High | $3.91 | $6.45 |
Technical Indicators
Market Signals| Indicator | HTT | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 38.71 | 27.14 |
| Support Level | $1.88 | $3.32 |
| Resistance Level | $2.69 | $4.34 |
| Average True Range (ATR) | 0.08 | 0.26 |
| MACD | -0.01 | -0.16 |
| Stochastic Oscillator | 23.53 | 10.06 |
Price Performance
Historical ComparisonAbout HTT High Templar Tech Limited American depositary shares each representing one Class A ordinary share
High Templar Tech Ltd is an enabler of AI-driven technology. High Templar is focusing on exploring business opportunities globally to satisfy clients' demand by leveraging its technology know-how and financial service capabilities.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.